These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

789 related items for PubMed ID: 28826571

  • 1. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H.
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [Abstract] [Full Text] [Related]

  • 2. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016 Oct; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

  • 3. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J.
    BMC Gastroenterol; 2022 Feb 04; 22(1):44. PubMed ID: 35120446
    [Abstract] [Full Text] [Related]

  • 4. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM, Swiss Inflammatory Bowel Diseases Cohort Study Group.
    Scand J Gastroenterol; 2014 Oct 04; 49(10):1207-18. PubMed ID: 25120029
    [Abstract] [Full Text] [Related]

  • 5. The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.
    Church PC, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths AM.
    Can J Gastroenterol Hepatol; 2018 Oct 04; 2018():3190548. PubMed ID: 30009157
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP.
    Am J Gastroenterol; 2017 Jan 04; 112(1):120-131. PubMed ID: 27958281
    [Abstract] [Full Text] [Related]

  • 9. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1776-1787. PubMed ID: 37921344
    [Abstract] [Full Text] [Related]

  • 10. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V, Fuhler GM, Edel AJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ, Dutch Delta IBD Group.
    J Crohns Colitis; 2015 Nov 03; 9(11):997-1003. PubMed ID: 26223842
    [Abstract] [Full Text] [Related]

  • 11. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
    Guasch M, Cañete F, Ordás I, Iglesias-Flores E, Clos A, Gisbert JP, Taxonera C, Vera I, Mínguez M, Guardiola J, Rivero M, Nos P, Gomollón F, Barrio J, de Francisco R, López-Sanromán A, Martín-Arranz MD, Garcia-Planella E, Camargo R, García-López S, de Castro L, Calvet X, Esteve M, Mañosa M, Domènech E, GETECCU-ENEIDA registry.
    J Gastroenterol Hepatol; 2020 Dec 03; 35(12):2080-2087. PubMed ID: 32350906
    [Abstract] [Full Text] [Related]

  • 12. A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF.
    Romero-Cara P, Torres-Moreno D, Pedregosa J, Vílchez JA, García-Simón MS, Ruiz-Merino G, Morán-Sanchez S, Conesa-Zamora P.
    Int J Med Sci; 2018 Dec 03; 15(1):10-15. PubMed ID: 29333082
    [Abstract] [Full Text] [Related]

  • 13. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A, Suzuki Y.
    Dig Dis Sci; 2018 Jan 03; 63(1):204-208. PubMed ID: 29209921
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, Dray-Spira R.
    Aliment Pharmacol Ther; 2017 Jan 03; 45(1):37-49. PubMed ID: 27781286
    [Abstract] [Full Text] [Related]

  • 15. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS, Han M, Park S, Cheon JH.
    Dig Dis Sci; 2020 May 03; 65(5):1436-1444. PubMed ID: 31677070
    [Abstract] [Full Text] [Related]

  • 16. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
    Blotière PO, Rudant J, Barré A, Racine A, Weill A, Peyrin-Biroulet L, Carbonnel F, Alla F.
    Dig Liver Dis; 2016 Jun 03; 48(6):620-5. PubMed ID: 27017107
    [Abstract] [Full Text] [Related]

  • 17. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, Rimmer JE, De La Revilla Negro J, Pavey H, Pele L, Brooks J, Moran GW, Irving PM, Limdi JK, Lamb CA, UK IBD BioResource Investigators , Parkes M, Raine T.
    J Crohns Colitis; 2024 Jun 03; 18(6):790-800. PubMed ID: 38041850
    [Abstract] [Full Text] [Related]

  • 18. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-Sánchez JN.
    Clin Gastroenterol Hepatol; 2019 Aug 03; 17(9):1788-1798.e2. PubMed ID: 30448599
    [Abstract] [Full Text] [Related]

  • 19. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD.
    J Crohns Colitis; 2014 Jun 03; 8(6):480-8. PubMed ID: 24268978
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 03; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.